BioCatalyst

YL202 should be intravenously infused — catalyst calendar

2 verified catalyst event(s) referencing YL202 should be intravenously infused, each linked to its official source. Verified as of 2026-06-22.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-07-30
in 1mo
ESTIMATED
 READOUT
A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 i
Phase 2 · Locally Advanced or Metastatic Breast Cancer
 MediLink Therapeutics (Suzhou) Co. YL202 should be intravenously infused ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
2026-11 (month)
in 4mo
ESTIMATED
 READOUT
A Study of YL202 in Selected Patients With Advanced Solid Tumors
Phase 2 · NSCLC, Breast Cancer
 MediLink Therapeutics (Suzhou) Co. YL202 should be intravenously infused ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.